University of North Carolina at Chapel Hill, Campus Box 7525, Chapel Hill, North Carolina 27599-7525, USA.
J Clin Microbiol. 2011 Jun;49(6):2086-92. doi: 10.1128/JCM.00589-11. Epub 2011 Apr 6.
The Centers for Disease Control and Prevention recently published updated guidelines for the use of interferon gamma release assays (IGRAs) to detect Mycobacterium tuberculosis. This document gives a balanced analysis of the strengths and weaknesses of IGRAs. To date, these assays have not been widely adopted in the United States by clinical laboratories. We have asked two experts, Thomas Alexander of Summa Health Care, who has adopted an IGRA for M. tuberculosis detection in his laboratory, and Melissa Miller of UNC Hospitals, who has evaluated one but has not chosen to adopt it, to explain how each reached this decision based on their experience with the test and the data that have been published concerning IGRA.
美国疾病控制与预防中心（Centers for Disease Control and Prevention）最近发布了更新的干扰素γ释放分析（interferon gamma release assays，IGRAs）检测结核分枝杆菌（Mycobacterium tuberculosis）使用指南。本文件对 IGRAs 的优缺点进行了平衡分析。迄今为止，这些检测方法尚未被美国临床实验室广泛采用。我们邀请了两位专家进行解读，他们是在其实验室中采用 IGRAs 检测结核分枝杆菌的辛玛医疗系统（Summa Health Care）的托马斯·亚历山大（Thomas Alexander），以及评估过该检测方法但尚未决定采用的北卡罗来纳大学医院（UNC Hospitals）的梅丽莎·米勒（Melissa Miller）。他们将根据自己的检测经验和已发表的关于 IGRAs 的数据，解释他们是如何做出这一决定的。
